Does Medicare Cover GLP-1 Medications in 2026?
Introduction
Medicare’s GLP-1 coverage in 2026 is a patchwork of yes, no, and “only if.” The short answer: Medicare covers GLP-1s for type 2 diabetes broadly, covers Wegovy® for cardiovascular risk reduction in some patients, covers Zepbound® for moderate-to-severe sleep apnea after the December 2024 FDA approval, and still legally cannot cover any GLP-1 for weight loss alone.
That last point trips up most people. Federal law (the Medicare Modernization Act of 2003) prohibits Part D coverage of drugs used for “anorexia, weight loss, or weight gain.” So if your doctor writes a prescription for Wegovy or Zepbound for weight management without another qualifying indication, Medicare will deny it, no matter how much you need it or how high your BMI is.
But there are real pathways to coverage. Let’s go through what works.
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.
Which GLP-1s Does Medicare Cover in 2026?
Medicare Part D covers these GLP-1 receptor agonists for type 2 diabetes with prior authorization: Ozempic® (semaglutide injection), Mounjaro® (tirzepatide), Trulicity® (dulaglutide), Victoza® (liraglutide), Rybelsus® (oral semaglutide), and Bydureon BCise (exenatide). Coverage tier and PA criteria vary by plan.
Quick Answer: Medicare Part D covers Ozempic, Mounjaro, and Trulicity for type 2 diabetes with prior authorization
For non-diabetes indications, coverage is limited. Wegovy is coverable for cardiovascular risk reduction under the SELECT trial-based indication. Zepbound is coverable for moderate-to-severe OSA. Saxenda® (liraglutide for weight management) is not Part D-coverable since it’s only indicated for weight loss.
The list of preferred GLP-1s differs by Part D plan. Some plans prefer Ozempic over Mounjaro for diabetes due to PBM rebate contracts. Others prefer the opposite. Check your specific plan’s formulary at medicare.gov or your plan’s website.
Does Medicare Cover GLP-1s for Diabetes?
Yes, generally with prior authorization. Standard Part D PA criteria for GLP-1 diabetes coverage require a documented A1C of 7.0% or higher, prior trial of metformin (or a contraindication), and either failure on a preferred GLP-1 (step therapy) or a clinical reason to skip step therapy.
The SURPASS trials (Frias et al. 2021 NEJM; SURPASS-2 and others) established tirzepatide’s superiority in A1C reduction, with up to 2.4% A1C drop at the 15 mg dose. The SUSTAIN trials established semaglutide’s efficacy. Both drugs are FDA-approved for type 2 diabetes and Medicare-covered.
Coverage typically lasts 6-12 months at a time and requires reauthorization with documentation of clinical response. About 95% of well-documented diabetes GLP-1 PA requests are approved in 2026 according to PBM aggregate data.
Does Medicare Cover Wegovy?
Yes, for cardiovascular risk reduction in adults with established cardiovascular disease and a BMI of 27 kg/m² or higher. This pathway opened in March 2024 after the SELECT trial (Lincoff et al. 2023 NEJM) showed semaglutide 2.4 mg weekly reduced major adverse cardiovascular events by 20% over 33 months in 17,604 patients with established CVD.
Established CVD means prior myocardial infarction, prior stroke, or symptomatic peripheral artery disease. The prescription must be coded for the CV indication, not for weight loss. ICD-10 codes I25.2 (old MI), I63.x (prior stroke), or I73.9 (PAD) plus Z68.27+ (BMI 27 or higher) typically satisfy the coding requirement.
Wegovy is not Part D-coverable for weight loss alone. Patients without established CVD have no Part D pathway for Wegovy in 2026.
Does Medicare Cover Zepbound?
Yes, for moderate-to-severe obstructive sleep apnea in adults with obesity, following the FDA’s December 2024 approval based on the SURMOUNT-OSA trial. The trial enrolled patients with AHI 15+ and BMI 30+, and showed substantial reductions in AHI and improvements in sleep quality compared to placebo over 52 weeks.
Coverage requires documented OSA via sleep study (PSG or HSAT) with AHI of 15 or higher, BMI of 30 or higher, and prescription coded with G47.33 (OSA) plus appropriate BMI Z-codes. Some plans also require documented CPAP intolerance or failure.
As of mid-2026, Part D plan implementation of the OSA pathway is still inconsistent. Some plans have fully integrated it into their PA criteria. Others are still processing OSA claims for Zepbound as weight-loss denials. Calling your plan to confirm OSA coverage is worth the time.
Does Medicare Cover Ozempic for Weight Loss?
No. Ozempic is FDA-approved for type 2 diabetes only. Off-label prescriptions of Ozempic for weight loss are denied under both the diabetes PA criteria (no A1C 7+) and the federal weight-loss exclusion. If your goal is semaglutide for weight or CV use, you need Wegovy, which is the same molecule at a different dose.
About 22% of Ozempic prescriptions in the U.S. in 2024 were estimated to be off-label for weight loss, but Medicare denial rates for these claims approach 100% once a coverage review is triggered.
What About Saxenda, Victoza, and Other GLP-1s?
Victoza is FDA-approved for type 2 diabetes and covered with PA. Saxenda is the same molecule (liraglutide) at a higher dose for weight management, and is not Part D-coverable. Trulicity is covered for diabetes. Bydureon and Byetta (exenatide) are covered for diabetes but rarely prescribed today given the better outcomes data on semaglutide and tirzepatide.
Rybelsus is oral semaglutide, Part D-covered for diabetes with PA. An oral semaglutide formulation for weight management is in late-stage trials and may receive FDA approval in 2026 or 2027, which could create a new weight-management coverage question for Medicare.
Key Takeaway: Zepbound is covered for moderate-to-severe OSA in patients with obesity following December 2024 FDA approval
What’s the Cost If Medicare Covers a GLP-1?
Copays depend on your plan’s tier placement and your benefit phase. In 2026, most Part D plans place GLP-1s on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), with copays ranging from $50-150/month in the initial coverage phase. After hitting the initial coverage limit, you enter the catastrophic phase where copays drop substantially.
The Inflation Reduction Act capped Medicare drug spending at $2,000 per year out-of-pocket starting in 2025, so the most you’ll pay annually for covered drugs is $2,000 regardless of list price. This is a major change that makes covered GLP-1s much more affordable for Medicare patients than they were in prior years.
For Part B-covered drugs (a few specialty injectables), the cost-sharing is 20% coinsurance after deductible. Most GLP-1s are Part D, not Part B.
What If Medicare Denies My GLP-1?
File an appeal. The five-level Medicare Part D appeals process gives you redetermination (level 1), IRE reconsideration (level 2), ALJ hearing (level 3), Appeals Council (level 4), and federal court (level 5). Most cases are resolved at levels 1 or 2.
Standard appeals are decided in 7 days at level 1 and 14 days at level 2. Expedited appeals are decided in 72 hours. File within 60 days of each denial. Include a letter of medical necessity from the prescriber citing relevant trial data and your specific clinical criteria.
About 35-45% of well-documented GLP-1 appeals are overturned. Appeals with thin documentation almost always fail.
What Are My Options If Medicare Won’t Cover Any GLP-1?
Three realistic options when Medicare coverage isn’t available. Manufacturer direct cash programs: Novo Nordisk’s NovoCare sells Wegovy vials for around $499/month, Eli Lilly’s LillyDirect sells Zepbound vials for around $549/month. These are vial formulations (not pens) and prices apply at all doses.
Compounded semaglutide and tirzepatide through licensed telehealth providers run $200-450/month. The FDA removed both drugs from the shortage list in 2024-2025, restricting 503B mass compounding. 503A pharmacies can still compound personalized formulations for individual patients with valid prescriptions.
A free assessment quiz from a licensed telehealth provider can determine clinical appropriateness and whether compounded therapy is the right fit. TrimRx and similar providers operate within current FDA and state pharmacy law for personalized 503A compounding.
Will Medicare Expand GLP-1 Coverage in 2026 or 2027?
Possibly. CMS has proposed expanding the Wegovy CV indication to include primary prevention (no prior CV event) in patients with very high CV risk. This is in rulemaking but not active policy. The Treat and Reduce Obesity Act (TROA) would amend federal law to allow weight-management coverage broadly, but has not passed Congress despite multiple introductions since 2013.
The Biden administration in late 2024 proposed a regulatory pathway to cover GLP-1s for obesity as a chronic disease, but the proposal is in extended rulemaking and faces legal challenges. Whether the current administration continues that path remains to be seen.
For 2026, plan on the existing coverage rules: diabetes, CV disease (Wegovy only), and OSA (Zepbound only) are coverable. Weight loss alone is not.
Bottom line: Manufacturer cash programs ($499-549/month) and compounded GLP-1s ($200-450/month) are realistic alternatives
FAQ
Does Medicare Advantage Cover GLP-1s Differently Than Original Medicare?
Medicare Advantage Part D plans follow the same federal restrictions. They cover GLP-1s for diabetes, Wegovy for CV indication, and Zepbound for OSA. Some MA plans, especially C-SNPs and D-SNPs, offer supplemental benefits that may include limited obesity drug coverage.
Can I Get GLP-1 Coverage Through Medigap or Supplemental Insurance?
No. Medigap covers gaps in original Medicare Part A and B, not Part D prescriptions. Supplemental drug coverage requires standalone Part D or Medicare Advantage Part D.
What’s the BMI Threshold for Wegovy Under Medicare?
BMI of 27 kg/m² or higher, plus established cardiovascular disease (prior MI, stroke, or symptomatic PAD).
Does Medicare Cover Compounded Semaglutide or Tirzepatide?
No. Medicare doesn’t cover compounded medications because they aren’t FDA-approved drugs. Compounded GLP-1s are cash-pay only.
How Do I Find Out If My Specific Part D Plan Covers Wegovy or Zepbound?
Check your plan’s formulary at medicare.gov via the Plan Finder, or call your plan’s member services. Ask specifically about the CV indication for Wegovy and the OSA indication for Zepbound, since blanket “weight loss” inquiries get false negatives.
Can I Switch Part D Plans to Get GLP-1 Coverage?
You can switch during the Annual Election Period (October 15 to December 7) or during a Special Enrollment Period if you qualify. All Part D plans face the same federal restriction on weight-loss coverage, but plans differ in how they implement the CV and OSA indications.
Does Medicare Cover Any Weight-loss Medications at All?
For older drugs like phentermine, no. Phentermine and similar appetite suppressants are not Part D-coverable. Bariatric surgery is covered under Part A/B with criteria. Behavioral counseling for obesity is covered under Part B. No oral weight-loss pill is Medicare-covered as of 2026.
Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.
Related Articles
Transforming Lives, One Step at a Time
Keep reading
GLP-1 Medications for Men Over 40: Testosterone, Metabolism, and Results
Weight loss for men over 40 operates under a different set of biological conditions than it did in your 20s or 30s, and GLP-1…
Long-Term Weight Loss Success on GLP-1: Habits That Actually Stick
GLP-1 medications are among the most effective weight loss tools ever developed, but they don’t produce identical long-term outcomes for everyone who takes them….
GLP-1 Maintenance vs Active Weight Loss: How Dosing Strategy Changes
Most of the conversation around GLP-1 medications focuses on the active weight loss phase: how fast results come, what side effects to expect, and…
